Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14227426 | 1.00 | CYP2D6 (0.70) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL14227427 | 1.00 | CYP2D6 (0.70) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL16931709 | 1.00 | CYP2D6 (0.70) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL16640675 | 1.00 | CYP2D6 (0.70) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL19841237 | 1.00 | CYP2D6 (0.70) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL20833321 | 1.00 | CYP2D6 (0.70) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL20833053 | 0.95 | CYP2D6 (0.63) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL20833279 | 0.95 | CYP2D6 (0.63) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL20833147 | 0.95 | CYP2D6 (0.63) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL20850797 | 0.93 | CYP2D6 (0.61) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117487048-A | Olefin polymerization catalyst, preparation method and application | 万华化学集团股份有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-112007045-A | Chiral control | 波涛生命科学有限公司 | 2020-12-01 | — | — | CN | disclosed |
| WO-2020191252-A1 | TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2020-09-24 | — | — | WO | disclosed |
| CN-104661664-B | Chiral control | 波涛生命科学有限公司 | 2020-07-03 | — | — | CN | disclosed |
| CN-104661664-A | Chiral control | WAVE LIFE SCIENCES PTY LTD | 2015-05-27 | — | — | CN | disclosed |
| US-7799952-B2 | Stereoselective method for the production of (R)-Dimepranol | RATIOPHARM GMBH (DE) | 2010-09-21 | — | — | US | disclosed |
| US-20090149677-A1 | Stereoselective Method for the Production of (R)-Dimepranol | RATIOPHARM GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-7507827-B2 | Stereoselective method for the production of Clopidogrel | RATIOPHARM GMBH (DE) | 2009-03-24 | — | — | US | disclosed |
| EP-1737868-B1 | STEREOSELECTIVE METHOD FOR THE PRODUCTION OF CLOPIDOGREL | RATIOPHARM GMBH (DE) | 2008-02-27 | — | — | EP | disclosed |
| US-20070219166-A1 | Stereoselective Method for the Production of Clopidogrel | RATIOPHARM GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-6307061-B2 | USEFUL AS AN ANALGESIC, ANESTHETIC, ANTI-INFLAMMATORY OR NEUROPROTECIVE AGENT | PFIZER INC. | 2001-10-23 | — | — | US | disclosed |
| US-6303602-B1 | USEFUL AS ANALGESIC, ANESTHETIC, ANTI-INFLAMMATORY OR NEUROPROTECTIVE AGENT, OR FOR THERAPY OF ARTHRITIS, STROKE OF FUNCTIONAL BOWEL DISEASE | PFIZER INC. | 2001-10-16 | — | — | US | disclosed |
| US-6294557-B1 | ANALGESIC AT CENTRAL NERVOUS SYSTEM IN THE MAMMALIAN SUBJECT. ALSO, THESE COMPOUNDS ARE INFLAMMATORY PAIN CAUSED, FOR EXAMPLE BY BURNS (INDUCED BY A CONTACT WITH HEAT, ACID OR THE OTHER RHEUMATISM OR THE LIKE, IN THE SAID SUBJECT. | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| US-6294569-B2 | ANALGESIC AT CENTRAL NERVOUS SYSTEM IN THE MAMMALIAN SUBJECT. ALSO, THESE COMPOUNDS ARE INFLAMMATORY PAIN CAUSED, FOR EXAMPLE BY BURNS (INDUCED BY A CONTACT WITH HEAT, ACID OR THE OTHER RHEUMATISM OR THE LIKE, IN THE SAID SUBJECT. | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| US-20010020024-A1 | Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists | ITO FUMITAKA (JP) | 2001-09-06 | — | — | US | disclosed |
| US-20010014683-A1 | Analgesics; side effect reduction | ITO FUMITAKA (JP) | 2001-08-16 | — | — | US | disclosed |
| US-20010011091-A1 | Analgesics | ITO FUMITAKA (JP) | 2001-08-02 | — | — | US | disclosed |
| US-20010009921-A1 | Less tendency to cause drug dependency, analgesic, anesthetic, anti-inflammatory or neuroprotective agent; subtype of opoid receptor | ITO FUMITAKA (JP) | 2001-07-26 | — | — | US | disclosed |
| US-20010008890-A1 | Useful as analgesic, anesthetic, antiinflammatory or neuroprotective agents and in treatment of arthritis, stroke, bowel disease | ITO FUMITAKA (JP) | 2001-07-19 | — | — | US | disclosed |
| US-6201007-B1 | OPIOID KAPPA RECEPTOR AGONISTS; ANALGESICS, ANESTHETICS, NEUROPROTECTIVE AND ANTIINFLAMMATORY AGENTS; STROKES, GASTROINTESTINAL DISORDERS | PFIZER INC. | 2001-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009921-A1 | Less tendency to cause drug dependency, analgesic, anesthetic, anti-inflammatory or neuroprotective agent; subtype of opoid receptor | OPRL1, OPRD1, OPRK1 | CYP2D6 450/4885CYP1A2 282/4885CYP2C19 1154/4885 |
| US-20010011091-A1 | Analgesics | OPRL1, OPRK1, OPRD1 | CYP2D6 128/4885CYP1A2 77/4885CYP2C19 543/4885 |
| US-20090149677-A1 | Stereoselective Method for the Production of (R)-Dimepranol | ADH5, ADH1A, ADH1C | CYP2D6 12/4885CYP1A2 26/4885CYP2C19 65/4885 |
| US-20010020024-A1 | Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists | OPRK1, OPRL1, OPRD1 | CYP2D6 1324/4885CYP1A2 363/4885CYP2C19 1984/4885 |
| US-20070219166-A1 | Stereoselective Method for the Production of Clopidogrel | CYP2C19, ADH1C, TBXA2R | CYP2D6 18/4885CYP1A2 22/4885CYP2C19 1/4885 |
| US-20010014683-A1 | Analgesics; side effect reduction | OPRL1, OPRK1, OPRD1 | CYP2D6 116/4885CYP1A2 75/4885CYP2C19 691/4885 |
| US-20010008890-A1 | Useful as analgesic, anesthetic, antiinflammatory or neuroprotective agents and in treatment of arthritis, stroke, bowel disease | OPRL1, NAP1L1, OPRK1 | CYP2D6 817/4885CYP1A2 433/4885CYP2C19 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.